Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | December 29, 2021 | December 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 29, 2021 · Filed December 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2026-12-28 | Direct | 29,091 |
Reported balance
After 2021-12-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-29 · Grant · Acquired 7,000 · Balance 29,091 F1: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MERIDIAN BIOSCIENCE INC
Report date January 31, 2023 · Filed January 31, 2023
Section 16 reporting ended · disclosed 2023-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Disposition to issuer · Disposed 16,424 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.18 · Expires 2025-08-14 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-31 · Disposition to issuer · Disposed 8,500 · Balance 0 F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.64 · Expires 2026-01-27 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-31 · Disposition to issuer · Disposed 8,500 · Balance 0 F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.80 · Expires 2027-01-25 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-31 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.20 · Expires 2028-01-25 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-01-31 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.97 · Expires 2029-01-24 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-01-31 · Disposition to issuer · Disposed 8,740 · Balance 0 F6: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.46 · Expires 2030-01-29 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-01-31 · Disposition to issuer · Disposed 17,205 · Balance 0 F7: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.36 · Expires 2031-01-27 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-01-31 · Disposition to issuer · Disposed 5,796 · Balance 0 F8: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.75 · Expires 2032-01-26 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-01-31 · Disposition to issuer · Disposed 5,656 · Balance 0 F9: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F6: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F7: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F8: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F9: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,656 | $13.25 Strike: $20.75 | $74,942.00 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 9 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,656 shares Expires 2032-01-26 F9 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F9 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F9 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,796 | $12.64 Strike: $21.36 | $73,261.44 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 8 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,796 shares Expires 2031-01-27 F8 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F8 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F8 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,205 | $23.54 Strike: $10.46 | $405,005.70 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 7 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,205 shares Expires 2030-01-29 F7 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F7 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F7 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,740 | $17.03 Strike: $16.97 | $148,842.20 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 6 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,740 shares Expires 2029-01-24 F6 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F6 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F6 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | $17.80 Strike: $16.20 | $213,600.00 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 5 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-01-25 F5 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F5 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F5 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | $21.20 Strike: $12.80 | $254,400.00 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 4 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-01-25 F4 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,500 | $15.36 Strike: $18.64 | $130,560.00 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 3 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2026-01-27 F3 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,500 | $15.82 Strike: $18.18 | $134,470.00 |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · derivative · entry 2 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2025-08-14 F2 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F2 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F2 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerCommon Stock | 16,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-001536 · doc1.xml · nonDerivative · entry 1 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 11:43 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 5,656 | $0.00 Strike: $20.75 | $0.00 |
DisclosureSEC source: 0001127602-22-002353 · form4.xml · derivative · entry 2 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,656 Underlying: Common Stock · 5,656 shares Expires 2032-01-26 F2 · derivative.exercise_date: These options are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 25, 2023. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 11:43 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 3,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002353 · form4.xml · nonDerivative · entry 1 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,424 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 25, 2023. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 18:03 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001213900-21-068185 · ownership.xml · derivative · entry 1 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,091 Underlying: Common shares · 7,000 shares Expires 2026-12-28 F1 · derivative.exercise_date: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 12:11 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 5,796 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0001127602-21-002944 · form4.xml · derivative · entry 2 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,796 Underlying: Common Stock · 5,796 shares Expires 2031-01-27 F2 · derivative.exercise_date: These options are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 26, 2022. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 12:11 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 1,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002944 · form4.xml · nonDerivative · entry 1 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,412 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in full (100%) on January 26, 2022. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 06:24 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-20-043371 · ownership.xml · derivative · entry 2 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common shares · 11,000 shares Expires 2025-12-15 F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00. F3 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest monthly as follows: 325 vest on 01/16/2021; and 305 vest on the 16th day of each of the following 35 months. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 06:24 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-20-043371 · ownership.xml · derivative · entry 1 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common shares · 7,000 shares Expires 2025-12-15 F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00. F2 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest 100% on the one year anniversary of the grant date (Dec 16, 2021) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 12:34 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 17,205 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001127602-20-002838 · form4.xml · derivative · entry 2 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,205 Underlying: Common Stock · 17,205 shares Expires 2030-01-30 F2 · derivative.exercise_date: These options are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 12:34 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 3,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-002838 · form4.xml · nonDerivative · entry 1 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,867 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 11:27 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 8,740 | $0.00 Strike: $16.97 | $0.00 |
DisclosureSEC source: 0001127602-19-002782 · form4.xml · derivative · entry 3 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,740 Underlying: Common Stock · 8,740 shares Expires 2029-01-24 F2 · derivative.exercise_date: These options are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 11:27 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 981 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-002782 · form4.xml · nonDerivative · entry 1 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 981 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| January 25, 2018 Filed Jan 26, 2018 14:02 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $16.20 | $0.00 |
DisclosureSEC source: 0001127602-18-002630 · form4.xml · derivative · entry 2 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: This award vests 25% every 90 days from the date of grant. Read SEC document |
| January 25, 2017 Filed Jan 26, 2017 12:17 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0001127602-17-002436 · form4.xml · derivative · entry 2 Sazdanoff Catherine · CIK 0001650901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: This award vests 25% every 90 days from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.